Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
114M
-
Number of holders
-
264
-
Total 13F shares, excl. options
-
94.4M
-
Shares change
-
+722K
-
Total reported value, excl. options
-
$8.19B
-
Value change
-
+$63.5M
-
Put/Call ratio
-
1.7
-
Number of buys
-
146
-
Number of sells
-
-106
-
Price
-
$86.79
Significant Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) as of Q2 2021
311 filings reported holding FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share as of Q2 2021.
FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) has 264 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 94.4M shares
of 114M outstanding shares and own 82.6% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (13M shares), VANGUARD GROUP INC (7.57M shares), ARK Investment Management LLC (7.48M shares), BlackRock Inc. (6.6M shares), FMR LLC (6.45M shares), Casdin Capital, LLC (3.4M shares), Johnson & Johnson Innovation - JJDC, Inc. (3.38M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.11M shares), Bellevue Group AG (2.61M shares), and STATE STREET CORP (2.05M shares).
This table shows the top 264 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.